Navigation Links
NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand
Date:9/23/2013

MIAMI, Sept. 23, 2013 /PRNewswire/ -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network as a key synergistic approach to aggressively build out our pipeline of products, we have aligned our plan with all regulatory requirements needed to gain expedited FDA approvals, Aligned Drug Portfolio selections and structured a plan to maximize production through our international globalization partnership.

The "Matured Drugs, Orphan Drugs and Discontinued Medications currently contribute to many of the existing deficiencies in all Healthcare Markets. These deficiencies have broadened the U.S. Healthcare Market's dependency on having to import over 80% of existing Prescription Medications from Manufacturers throughout the world.  In addition, due the discontinuation of many high value Matured Drugs; the Healthcare market has reached a record high in FDA Short Supply.  This problem has created a multi-billion dollar dependency on Non-FDA Approved Compounding Pharmacies.

At NSB, our goal is to ensure the Healthcare Markets continued access to these important medications. All products in the NSB portfolio share development factors that Cross Over the Human Healthcare market yielding additional indications for use in Companion Animals. These initiatives will optimize, secure and diversify the product portfolio yielding the highest revenue potential while maintaining the most secure supply chain.

"Due to current market conditions, "said Robert DiCrisci, President, CEO of NextSource Biotechnology, we are strategically positioned to launch a product portfolio that will further anchor our position as the leader in product re-branding and product diversification of the "Matured & Orphan Drugs". Our future remains focused on maximizing our existing portfolio of products, while maintaining flexibility to bring in additional products as demands change."

NSB's core competencies in marketing and business development enabled us to engage in high volume distribution agreements with the top Wholesalers in the US Market which currently account for high volume nationwide distribution on over 70% of our revenue.

NextSource Biotechnology recently re-introduced the Lomustine (CCNU) product formally known as CeeNu® through an exclusive manufacturing partnership with CordenPharma, Latina. This business development was the result of a divestiture between Bristol-Myers Squibb (BMS) and CordenPharma\NextSource Biotechnology. NSB is currently in the final stage of normalizing the shortage of Lomustine (formally known as CeeNu®) in the U.S. healthcare market. NSB is projected to be off short supply by the close of Q3, 2013. The medication will continue to be distributed under the Lomustine label pending FDA "Brand" name review and approval.  

Lomustine has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors—both primary and metastatic, in patients who have already received appropriate surgical and/or radio therapeutic procedures.
Hodgkin's disease—secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

About our Partner: CordenPharma is an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies link their requirements for product success with their patients' healthier lives.

Formed as a pharmaceutical branch of International Chemical Investors Group in 2006, CordenPharma provides specialized technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services.


'/>"/>
SOURCE NextSource Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
2. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
3. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
4. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
5. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
6. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
7. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
8. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
9. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
10. Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
11. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... updated financial guidance for 2016 on Thursday, December 15, ... that day with the investment community and media to ... conference call will begin at 10 a.m. ET. Investors, ... webcast of the conference call through a link that ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with ... that works for them. When an inventor from Suisun City, Calif., was unsuccessful in ... share it with others. , He developed a prototype for PRO GO MASSAGE to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi ... be included in the 2016 “Guide to America’s Top Plastic Surgeons” for seven ... amalgamation of their education, experience, and professional associations. , One the most ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
(Date:12/2/2016)... Honolulu, Hawaii (PRWEB) , ... December 02, 2016 ... ... 3, 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, ... (CME) in the field of pain management. , The demand for supplemental ...
Breaking Medicine News(10 mins):